Clovis Oncology (XTRA:C6O) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

C6O Stock Overview

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. More details

C6O fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Revenue is forecast to grow 48.64% per year

Earnings have grown 5.6% per year over the past 5 years

Trading at good value compared to peers and industry

Risk Analysis

Shares are highly illiquid

Negative shareholders equity

Has less than 1 year of cash runway

Does not have a meaningful market cap (€14M)

+ 1 more risk

Clovis Oncology, Inc. Competitors

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€20.6m

Paion

XTRA:PA8

€2.6m

Epigenomics

XTRA:ECX

€616.0k

Price History & Performance

Summary of all time highs, changes and price drops for Clovis Oncology
Historical stock prices
Current Share Price	US$0.091
52 Week High	US$3.00
52 Week Low	US$0.09
Beta	0.95
11 Month Change	0%
3 Month Change	0%
1 Year Change	-94.05%
33 Year Change	-97.84%
5 Year Change	n/a
Change since IPO	-99.87%

Recent updates

Shareholder Returns

	C6O	DE Biotechs	DE Market
7D	0%	0.8%	0.8%
1Y	-94.1%	-18.3%	8.6%

Return vs Industry: C6O underperformed the German Biotechs industry which returned -5.8% over the past year.

Return vs Market: C6O underperformed the German Market which returned -13% over the past year.

Price Volatility

Is C6O's price volatile compared to industry and market?
C6O volatility
C6O Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: C6O's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine C6O's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	413	Patrick Mahaffy	www.clovisoncology.com

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Clovis Oncology, Inc. Fundamentals Summary

How do Clovis Oncology's earnings and revenue compare to its market cap?
C6O fundamental statistics
Market cap	€12.78m
Earnings (TTM)	-€233.87m
Revenue (TTM)	€123.50m

0.1x

P/S Ratio

-0.1x

P/E Ratio

Is C6O overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
C6O income statement (TTM)
Revenue	US$133.02m
Cost of Revenue	US$31.59m
Gross Profit	US$101.43m
Other Expenses	US$353.33m
Earnings	-US$251.91m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-1.74
Gross Margin	76.25%
Net Profit Margin	-189.37%
Debt/Equity Ratio	-158.0%

How did C6O perform over the long term?

See historical performance and comparison

This company listing is no longer active

C6O Stock Overview

Rewards

Risk Analysis

Clovis Oncology, Inc. Competitors

XTRA:CNW

€6.5m

XTRA:MDG1

€20.6m

XTRA:PA8

€2.6m

XTRA:ECX

€616.0k

Price History & Performance

Recent News & Updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Recent updates

Clovis Oncology, Inc.(OTCPK:CLVS.Q) dropped from NASDAQ Composite Index

Clovis Oncology, Inc.(NasdaqGS:CLVS) dropped from S&P TMI Index

Nasdaq to Delist Common Stock of Clovis Oncology from Exchange

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Filed for Bankruptcy

Clovis Oncology, Inc. Discusses the Overall Survival (Os) Data from the ARIEL3 Clinical Trial with FDA t

Insufficient new directors

Third quarter 2022 earnings released: US$0.39 loss per share (vs US$0.56 loss in 3Q 2021)

Clovis Oncology, Inc Announces Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Cvis Oncncology, Inc. Announces Positive Top-Line Data from the Phase 3, Open-Label, Multicenter, Randomized Triton3 Trial

Clovis Oncology, Inc. Submits Applications for Rubraca® Label Expansion in the US and European Union as First-Line Maintenance Treatment in Women with Advanced Ovarian Cancer

Clovis Oncology’s Rubraca (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

Second quarter 2022 earnings released: US$0.49 loss per share (vs US$0.61 loss in 2Q 2021)

Clovis Oncology, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 At SNMMI Annual Meeting

First quarter 2022 earnings released: US$0.43 loss per share (vs US$0.64 loss in 1Q 2021)

Now 20% undervalued

Insufficient new directors

Now 20% undervalued after recent price drop

Clovis Oncology, Inc. to Report Q1, 2022 Results on May 04, 2022

Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022

Now 23% undervalued after recent price drop

Clovis Oncology, Inc. Announces A Trial-In-Progress Poster Detailing the Phase 1 Portion of the LuMIERE Clinical Study for Its Targeted Radiotherapy Candidate FAP-2286

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Clovis Oncology, Inc. Provides Preliminary Unaudited Earnings Guidance for the Quarter and Year Ended December 31, 2021

Insufficient new directors

Third quarter 2021 earnings released: US$0.56 loss per share (vs US$0.89 loss in 3Q 2020)

Clovis Oncology, Inc. Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland

Clovis Oncology, Inc. Provides an Update on the Clinical Development Programs

Second quarter 2021 earnings released: US$0.61 loss per share (vs US$1.15 loss in 2Q 2020)

Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment

Clovis Oncology, Inc. Highlights Rubraca® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

First quarter 2021 earnings released: US$0.64 loss per share (vs US$1.39 loss in 1Q 2020)

Clovis Oncology, Inc. Announces First Presentation of Data from the Phase 3 ARIEL4 Study of Rubraca® (rucaparib) at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer

Revenue beats expectations

Full year 2020 earnings released: US$4.38 loss per share (vs US$7.43 loss in FY 2019)

Clovis Oncology, Inc. Presents Data in Advanced Prostate Cancer At Asco 2021 Genitourinary Cancers Symposium Virtual Meeting

New 90-day high: €8.10

New 90-day high: €4.77

Clovis Oncology, Inc. to Report Q4, 2020 Results on Feb 23, 2021

Clovis Oncology, Inc. Completes Submission of Two Investigational New Drug Applications to the U.S. Food and Drug Administration for FAP-2286

Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation

Third quarter 2020 earnings released: US$0.89 loss per share

Revenue misses expectations

Clovis Oncology, Inc. announced that it expects to receive $50 million in funding

New 90-day low: €3.78

Shareholder Returns

Price Volatility

About the Company

Clovis Oncology, Inc. Fundamentals Summary

0.1x

-0.1x

Earnings & Revenue